“The findings of this study will influence shared decision-making between chronic kidney disease patients and the heart team,” one specialist observed. 

The cardiac models were created using human stem cells. Each one is able to beat in less than a week. 

According to Medtronic, its Intrepid TTVR system helps meet a “large, unmet clinical need.”

The authors examined data from more than 134,000 TAVR patients, noting that 65% of endocarditis infections occurred within one year after the procedure. 

The patient-specific models were designed to help clinicians prepare for transcatheter aortic valve replacement (TAVR) procedures.

Patient access to TAVR centers is often limited in rural areas where resources are in short supply.

Treatment with probenecid led to “improved cardiac function and exercise performance” in patients with congenital univentricular circulation.

The new research out of Germany suggests both strategies are safe and effective for patients. 

Overall, the simulations inspired clinicians to change part of the treatment plan for 16 of 42 patients.  

The overall procedural technical success rate, researchers reported, was 96.8%.